Stocktoria
AYTU BIOPHARMA, INC AYTU
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-10-20
AYTU BIOPHARMA, INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% |
| Operating margin | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% |
| Net margin | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% |
| FCF margin | -3.3% | -2.6% | — | — | — |
| Return on assets | -10.9% | -13.4% | -12.5% | -79.0% | -21.9% |
| Return on equity | -71.5% | -57.2% | -43.3% | -245.5% | -42.4% |
| Debt / equity | 0.57× | 0.39× | 0.38× | 0.34× | — |
| Current ratio | 1.26 | 0.99 | 1.06 | 0.93 | 0.96 |
| Revenue growth | 1.8% | -39.3% | 11.1% | 47.3% | 137.5% |
Source: SEC EDGAR filings · CIK 0001385818 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.